Optibrium, a provider of software solutions for drug
discovery, and Cresset, a software and services provider, announced an
agreement to collaborate on the development of next-generation platforms. The
companies will work together, combining approaches to help drug discovery
projects quickly identify novel, potent compounds with a high chance of success
downstream.
The collaboration will involve a two-way exchange of
technologies: Optibrium’s ADME1 models, currently provided as a plug-in module
for its StarDrop software platform, will be made available to users of
Cresset’s desktop applications. Similarly, Cresset’s FieldAlign software, which
helps chemists understand the 3D structure-activity-relationship of their
chemistry in order to design active compounds, will be made available as an
optional plug-in module for StarDrop, which helps project teams to confidently
target compounds with a good balance of properties for their therapeutic
objectives.
Achieving a combination of potency with appropriate ADME and
safety properties is essential to the discovery of high-quality drug
candidates. Cresset’s molecular field technology provides insight into the
biological activity, properties, and interactions of molecules, which enables
biologically meaningful comparisons that are not limited by 2D structure. Optibrium’s
StarDrop platform helps to guide decisions on the design and selection of
compounds by integrating in silico
and experimentally measured properties using a multi-parameter optimization
approach, chemical space and Glowing Molecule visualizations, and predictive modeling.
The technology shared under this collaboration will form new
components in upcoming releases of Optibrium’s StarDrop and Cresset’s desktop
applications.
Optibrium, www.optibrium.com
